SG Americas Securities LLC decreased its position in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 43.1% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 25,534 shares of the company’s stock after selling 19,309 shares during the period. SG Americas Securities LLC’s holdings in Guardant Health were worth $780,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Guardant Health by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock worth $102,000 after purchasing an additional 796 shares during the last quarter. Fiduciary Alliance LLC increased its position in shares of Guardant Health by 7.6% during the 4th quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company’s stock worth $363,000 after purchasing an additional 836 shares during the last quarter. JNBA Financial Advisors acquired a new position in shares of Guardant Health during the 3rd quarter worth approximately $26,000. Wexford Capital LP increased its position in shares of Guardant Health by 13.0% during the 3rd quarter. Wexford Capital LP now owns 10,081 shares of the company’s stock worth $231,000 after purchasing an additional 1,158 shares during the last quarter. Finally, Ashton Thomas Securities LLC acquired a new position in shares of Guardant Health during the 3rd quarter worth approximately $34,000. Institutional investors own 92.60% of the company’s stock.
Insiders Place Their Bets
In other news, Director Musa Tariq sold 2,320 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the transaction, the director now owns 2,676 shares in the company, valued at $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Meghan V. Joyce sold 2,896 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now owns 7,648 shares in the company, valued at $228,675.20. This represents a 27.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,548 shares of company stock worth $179,782. Corporate insiders own 5.50% of the company’s stock.
Guardant Health Price Performance
Guardant Health (NASDAQ:GH – Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.33). The business had revenue of $191.48 million for the quarter, compared to analyst estimates of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.73) EPS. Equities analysts expect that Guardant Health, Inc. will post -3.44 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on GH. JPMorgan Chase & Co. boosted their target price on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Sanford C. Bernstein decreased their target price on Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, October 30th. Barclays began coverage on Guardant Health in a report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 target price on the stock. Guggenheim reissued a “buy” rating on shares of Guardant Health in a report on Wednesday, January 22nd. Finally, Leerink Partners decreased their target price on Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Sixteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $42.63.
View Our Latest Analysis on Guardant Health
Guardant Health Profile
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Recommended Stories
- Five stocks we like better than Guardant Health
- What Is WallStreetBets and What Stocks Are They Targeting?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Steel Stocks Soaring After Tariff Announcements
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.